

**Listing of the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

- 1                    1 (currently amended): A molecule of the structure **A – X – B**, wherein  
2                    **B** is a peptide portion of about 5 to about 20 basic amino acid residues, which is  
3 suitable for cellular uptake,  
4                    **A** is a peptide portion of about 2 to about 20 acidic amino acid residues, which  
5 when linked with portion **B** is effective to inhibit or ~~prevent~~ cellular uptake of portion **B**, and  
6                    **X** is a linker of about 2 to about 100 atoms joining **A** with **B**, which can be  
7 cleaved under physiological conditions, wherein **X** comprises the sequence of SEQ ID NO: 1.
- 1                    2 (original): The molecule of claim 1, wherein said peptide portion **A** comprises  
2 about 5 to about 9 glutamates or aspartates.
- 1                    3 (original): The molecule of claim 2, wherein said peptide portion **A** comprises  
2 about 5 to about 9 consecutive glutamates or aspartates.
- 1                    4 (original): The molecule of claim 1, wherein said peptide portion **B** comprises  
2 about 9 to about 16 arginines.
- 1                    5 (original): The molecule of claim 4, wherein said peptide portion **B** comprises  
2 about 9 to about 16 consecutive arginines.
- 1                    6 (original): The molecule of claim 1, wherein said peptide portion **A** comprises  
2 D-amino acids.
- 1                    7 (original): The molecule of claim 1, wherein said peptide portion **B** comprises  
2 D-amino acids.

1                   8 (original): The molecule of claim 1, wherein said peptide portion **A** consists of  
2 D-amino acids.

1                   9 (original): The molecule of claim 1, wherein said peptide portion **B** consists of  
2 D-amino acids.

1                   10 (original): The molecule of claim 1, wherein said peptide portions **A** and **B**  
2 consists of D-amino acids.

1                   11 (currently amended): A molecule for transporting a cargo moiety across a cell  
2 membrane of the structure **A – X – B – C**, wherein

3                   **C** is a portion comprising a cargo moiety,

4                   **B** is a peptide portion of about 5 to about 20 basic amino acid residues, which is  
5 suitable for cellular uptake, is covalently linked to portion **C**, and is effective to enhance  
6 transport of cargo portion **C** across a cell membrane,

7                   **A** is a peptide portion of about 2 to about 20 acidic amino acid residues, which  
8 when linked with portion **B** is effective to inhibit ~~or prevent~~ cellular uptake of **B - C**, and

9                   **X** is a cleavable linker of about 2 to about 100 atoms joining **A** with **B – C**, which  
10 can be cleaved under physiological conditions, wherein **X** comprises the sequence of SEQ ID

11 NO: 1.

1                   12 (original): The molecule of claim 11, wherein said peptide portion **A**  
2 comprises amino acids selected from the group of acidic amino acids consisting of glutamate and  
3 aspartate.

1                   13 (original): The molecule of claim 11, wherein said peptide portion **B**  
2 comprises amino acids selected from the group of basic amino acids consisting of arginine and  
3 histidine.

1                   14 (original): The molecule of claim 11, wherein said cargo portion **C** is selected  
2 from the group of cargo moieties consisting of a fluorescent moiety, a fluorescence-quenching

3 moiety, a radioactive moiety, a radiopaque moiety, a paramagnetic moiety, a nanoparticle, a  
4 vesicle, a molecular beacon, a marker, a marker enzyme, a contrast agent, a chemotherapeutic  
5 agent, and a radiation-sensitizer.

1 15 (original): The molecule of claim 14, wherein the cargo portion **C** comprises  
2 a contrast agent for diagnostic imaging.

1 16 (original): The molecule of claim 14, wherein the cargo portion **C** comprises  
2 a radiation sensitizer for radiation therapy.

1 17 (original): The molecule of claim 11, wherein said peptide portion **A**  
2 comprises about 5 to about 9 glutamates or aspartates.

1 18 (original): The molecule of claim 17, wherein said peptide portion **A**  
2 comprises about 5 to about 9 consecutive glutamates or aspartates.

1 19 (original): The molecule of claim 11, wherein said portion peptide **B**  
2 comprises between about 9 to about 16 arginines.

1 20 (original): The molecule of claim 19, wherein said peptide portion **B**  
2 comprises between about 9 to about 16 consecutive arginines.

1 21 (original): The molecule of claim 11, wherein said peptide portion **A**  
2 comprises D-amino acids.

1 22 (original): The molecule of claim 11, wherein said peptide portion **B**  
2 comprises D-amino acids.

1 23 (original): The molecule of claim 11, wherein said peptide portion **A** consists  
2 of D-amino acids.

1 24 (original): The molecule of claim 11, wherein said peptide portion **B** consists  
2 of D-amino acids.

1                   25 (original): The molecule of claim 11, wherein said peptide portions **A** and **B**  
2 consist of D-amino acids.

1                   26 (original): The molecule of claim 25, wherein said peptide portion **B** consists  
2 of D-arginine amino acids.

1                   27 (original): The molecule of claim 11, wherein said peptide portion **A** is  
2 located at a terminus of a polypeptide chain comprising **B – C**.

1                   28 (original): The molecule of claim 11, wherein said peptide portion **A** is  
2 located at the amino terminus of a polypeptide chain comprising **B – C**.

1                   29 (original): The molecule of claim 11, wherein said peptide portion **A** is linked  
2 near to or at the amino terminus of a polypeptide chain comprising **B – C**.

1                   30 (original): The molecule of claim 11, wherein said peptide portion **A** is linked  
2 near to or at the carboxy terminus of a polypeptide chain comprising **B – C**.

1                   31 (original): The molecule of claim 11, wherein **B – C** comprises a polypeptide  
2 chain having ends consisting of a **B**-side terminus and a **C**-side terminus, and wherein cleavable  
3 linker **X** is disposed near or at said **B**-side terminus.

1                   32 (original): The molecule of claim 11, wherein **B – C** comprises a polypeptide  
2 chain having ends consisting of a **B**-side terminus and a **C**-side terminus, and wherein cleavable  
3 linker **X** is disposed near or at said **C**-side terminus.

33-36 (canceled)

1                   37 (original): The molecule of claim 11, wherein cleavable linker **X** comprises  
2 aminocaproic acid.

38-44 (canceled)

1                   45 (original): The molecule of claim 11, comprising a plurality of cleavable  
2   linkers **X** linking a portion **A** to a structure **B – C**.

1                   46 (currently amended): A pharmaceutical composition comprising:  
2                   A molecule of the structure **A – X – B**, wherein  
3                   **B** is a peptide portion of about 5 to about 20 basic amino acid residues, which is  
4   suitable for cellular uptake,  
5                   **A** is a peptide portion of about 2 to about 20 acidic amino acid residues, which  
6   when linked with portion **B** is effective to inhibit ~~or prevent~~ cellular uptake of portion **B**, and  
7                   **X** is a cleavable linker of about 3 to about 30 atoms joining **A** with **B**, which can  
8   be cleaved under physiological conditions, wherein **X** comprises the sequence of SEQ ID NO: 1;  
9   and  
10                  a pharmaceutically acceptable carrier.

1                   47 (previously presented): The pharmaceutical composition of claim 46, wherein  
2                   said portion **A** has between about 5 to about 9 acidic amino acid residues, and said  
3   portion **B** has between about 9 to about 16 basic amino acid residues.

1                   48 (original): The pharmaceutical composition of claim 46 or 47, further  
2   comprising a portion **C** covalently attached to said portion **B** and comprising a cargo moiety.

1                   49 (withdrawn): A method of modulating cellular uptake of a peptide **B** of about  
2   5 to about 20 basic amino acid residues, which is suitable for cellular uptake, comprising:  
3                   linking said peptide **B** to a peptide **A** of about 2 to about 20 acidic amino acid  
4   residues with a cleavable linker **X** of about 3 to about 30 atoms, which can be cleaved under  
5   physiological conditions and  
6                   cleaving said cleavable linker **X** effective to separate peptide **B** from molecule **A**.

1                   50 (withdrawn): A method of modulating cellular uptake of a cargo moiety **C**,  
2   comprising:

3 covalently attaching a cargo moiety **C** to a peptide **B** of about 5 to about 20 basic  
4 amino acid residues to form a molecule **B – C**;

5 linking said molecule **B – C** to a peptide **A** of about 2 to about 20 acidic amino  
6 acid residues with a cleavable linker **X** of about 3 to about 30 atoms, and

7 cleaving said cleavable linker **X** effective to separate **B – C** from said peptide **A**.

1 51 (withdrawn): A nucleic acid encoding a molecule of the structure **A – X – B**,  
2 wherein

3 **B** is a peptide of about 5 to about 20 basic amino acid residues, which is suitable  
4 for cellular uptake,

5 **A** is a peptide of about 2 to about 20 acidic amino acid residues, which when  
6 linked with peptide **B** is effective to inhibit or prevent cellular uptake of peptide **B**, and

7 **X** is a cleavable linker portion of between 1 and 10 amino acid residues joining **A**  
8 with **B**, which can be cleaved under physiological conditions.

1 52 (withdrawn): A nucleic acid encoding a molecule of the structure **A – X – B –**  
2 **C**, wherein

3 **C** is a peptide cargo moiety,

4 **B** is a peptide of about 5 to about 20 basic amino acid residues, which is suitable  
5 for cellular uptake,

6 **A** is a peptide of about 2 to about 20 acidic amino acid residues, which when  
7 linked with peptide **B** is effective to inhibit or prevent cellular uptake of peptide **B – C**, and

8 **X** is a cleavable linker portion of between 1 and 10 amino acid residues joining **A**  
9 with **B – C** which can be cleaved under physiological conditions.

1 53 (withdrawn): A molecule for transporting a fluorescent cargo moiety across a  
2 cell membrane of the structure **Q – A – X – B – C**, wherein

3 **C** is a portion comprising a fluorescent cargo moiety,

4                    **B** is a peptide portion of about 5 to about 20 basic amino acid residues, which is  
5 suitable for cellular uptake, is covalently linked to portion **C**, and is effective to enhance  
6 transport of cargo portion **C** across a cell membrane,

7                    **Q** is a quencher moiety attached to **A** and effective to quench fluorescence from  
8 fluorescent cargo **C**;

9                    **A** is a peptide portion of about 2 to about 20 acidic amino acid residues, which  
10 when linked with portion **B** is effective to inhibit or prevent cellular uptake of **B – C**, and

11                    **X** is a cleavable linker of about 2 to about 100 atoms joining **A** with **B – C**, which  
12 can be cleaved under physiological conditions.

54 -55 (canceled)

1                    56 (original): The molecule of claim 11, comprising a single cargo portion **C**  
2 linked to a plurality of portions **B**, each of portions **B** being linked to a cleavable linker portion **X**  
3 linked to an acidic portion **A**.